Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BOL 148/neuroprotectant agent combination therapy - Havn Life Sciences

X
Drug Profile

BOL 148/neuroprotectant agent combination therapy - Havn Life Sciences

Alternative Names: BOL-148/neuroprotectant agent combination therapy - Havn Life Sciences; Neuroprotectant agent/BOL 148 combination therapy - Havn Life Sciences

Latest Information Update: 16 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bolt Biotherapeutics
  • Class Analgesics; Antidementias; Antidepressants; Anxiolytics; Ergolines; Ergot alkaloids; Neuroprotectants; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Serotonin 5-HT2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cluster headache

Most Recent Events

  • 02 Jun 2021 Havn Life Sciences acquires IP rights from Bolt Biotherapeutics
  • 02 Jun 2021 Early research in Cluster headache in Canada (unspecified route)
  • 02 Jun 2021 Havn Life Sciences announces intention to launch Neuroprotectant agent/BOL 148 combination therapy in four years

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top